BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1295 related articles for article (PubMed ID: 15854350)

  • 41. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
    Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS
    Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867
    [TBL] [Abstract][Full Text] [Related]  

  • 44. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Anal Cell Pathol (Amst); 2010; 33(3):121-32. PubMed ID: 20978319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
    Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
    Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.
    Esteban MA; Tran MG; Harten SK; Hill P; Castellanos MC; Chandra A; Raval R; O'brien TS; Maxwell PH
    Cancer Res; 2006 Apr; 66(7):3567-75. PubMed ID: 16585181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The m
    Xiao Y; Thakkar KN; Zhao H; Broughton J; Li Y; Seoane JA; Diep AN; Metzner TJ; von Eyben R; Dill DL; Brooks JD; Curtis C; Leppert JT; Ye J; Peehl DM; Giaccia AJ; Sinha S; Rankin EB
    Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21441-21449. PubMed ID: 32817424
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Mutation of von Hippel-Lindau gene and expression of vascular endothelial growth factor in sporadic clear cell renal cell carcinoma and their relationships to angiogenesis].
    Zhang N; Gong K; Guo HF; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1620-4. PubMed ID: 15569457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
    Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
    Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors.
    Kim CM; Vocke C; Torres-Cabala C; Yang Y; Schmidt L; Walther M; Linehan WM
    J Urol; 2006 May; 175(5):1908-14. PubMed ID: 16600797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting renal cell carcinoma with a HIF-2 antagonist.
    Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
    Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
    Wolf C; Smith S; van Wijk SJL
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vhl deletion in renal epithelia causes HIF-1α-dependent, HIF-2α-independent angiogenesis and constitutive diuresis.
    Schönenberger D; Rajski M; Harlander S; Frew IJ
    Oncotarget; 2016 Sep; 7(38):60971-60985. PubMed ID: 27528422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
    Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
    Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
    Kroeger N; Klatte T; Chamie K; Rao PN; Birkhäuser FD; Sonn GA; Riss J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    Cancer; 2013 Apr; 119(8):1547-54. PubMed ID: 23335244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma.
    Ebru T; Fulya OP; Hakan A; Vuslat YC; Necdet S; Nuray C; Filiz O
    Int Braz J Urol; 2017; 43(3):440-454. PubMed ID: 27583351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
    Lee S; Garner EI; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2007 Aug; 106(2):311-7. PubMed ID: 17532031
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
    Kaelin WG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.